Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 7/20 | 0.42 |
| ▸ | MMP2 | P08253 | 6/20 | 0.42 |
| ▸ | MMP13 | P45452 | 6/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348533 | 0.86 | ADAMTS4 (0.38) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL5115513 | 0.80 | NPC1 (0.38) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL3118465 | 0.76 | ALDH1A1 (0.38) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL3125369 | 0.76 | ADAMTS4 (0.36) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL3113106 | 0.74 | ADAMTS4 (0.40) | ADAMTS4MMP2MMP13ADAM17MMP14 | |
| SCHEMBL30823619 | 0.74 | GAA (0.41) | MEN1KMT2A | |
| SCHEMBL1180196 | 0.74 | GAA (0.41) | MEN1KMT2A | |
| SCHEMBL3516005 | 0.72 | EPHX2 (0.34) | CNR2EPHX2 | |
| SCHEMBL5718625 | 0.71 | GAA (0.39) | MEN1KMT2A | |
| SCHEMBL30723203 | 0.71 | GAA (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2219448-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | Myriad Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009065035-A1 | THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS | MYRIAD GENETICS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292255-A1 | Therapeutic Compounds and Their Use in Treating Diseases and Disorders | VHL, CLN6, CFTR | ADAMTS4 577/4885MMP2 3089/4885MMP13 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.